| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Microbiology and Immunology Training Program, Boston University School of Medicine, and
Evans Memorial Department of Medicine, Section of Infectious Diseases, Boston Medical Center, Boston, MA 02118
Ag mannosylation represents a promising strategy to augment vaccine immunogenicity by targeting Ag to mannose receptors (MRs) on dendritic cells. Because fungi naturally mannosylate proteins, we hypothesized that Ags engineered in fungi would have an enhanced capacity to stimulate T cell responses. Using the model Ag OVA, we generated proteins that differentially expressed N- and O-linked mannosylation in the yeast Pichia pastoris and compared them to their unglycosylated counterparts produced in Escherichia coli. We found that yeast-derived OVA proteins containing N-linkages, extensive O-linkages, or both were more potent than the unmannosylated Ags at inducing OVA-specific CD4+ T cell proliferation. This elevated response to fungal Ags was inhibited by mannan, suggesting involvement of MRs. However, the macrophage MR (CD206) was not essential, because macrophage MR-deficient dendritic cells were fully competent in presenting yeast-derived OVA Ags. Thus, the use of fungal glycosylation to provide N-linked and/or extensive O-linked mannosylation increased the capacity of the model Ag OVA to stimulate Ag-specific T cell responses in an MR-dependent manner. These data have implications for vaccine design by providing proof of principle that yeast-derived mannosylation can enhance immunogenicity.
This article has been cited by other articles:
|
|
 |
|
  A. Cambi, M. G. Netea, H. M. Mora-Montes, N. A. R. Gow, S. V. Hato, D. W. Lowman, B.-J. Kullberg, R. Torensma, D. L. Williams, and C. G. Figdor Dendritic Cell Interaction with Candida albicans Critically Depends on N-Linked Mannan J. Biol. Chem., July 18, 2008; 283(29): 20590 - 20599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Dan, R. M. Kelly, C. K. Lee, and S. M. Levitz Role of the Mannose Receptor in a Murine Model of Cryptococcus neoformans Infection Infect. Immun., June 1, 2008; 76(6): 2362 - 2367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rachini, D. Pietrella, P. Lupo, A. Torosantucci, P. Chiani, C. Bromuro, C. Proietti, F. Bistoni, A. Cassone, and A. Vecchiarelli An Anti-{beta}-Glucan Monoclonal Antibody Inhibits Growth and Capsule Formation of Cryptococcus neoformans In Vitro and Exerts Therapeutic, Anticryptococcal Activity In Vivo Infect. Immun., November 1, 2007; 75(11): 5085 - 5094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dasgupta, A.-M. Navarrete, J. Bayry, S. Delignat, B. Wootla, S. Andre, O. Christophe, M. Nascimbeni, M. Jacquemin, L. Martinez-Pomares, et al. A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes PNAS, May 22, 2007; 104(21): 8965 - 8970. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. McKenzie, P. R. Taylor, R. J. Stillion, A. D. Lucas, J. Harris, S. Gordon, and L. Martinez-Pomares Mannose Receptor Expression and Function Define a New Population of Murine Dendritic Cells J. Immunol., April 15, 2007; 178(8): 4975 - 4983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kogelberg, B. Tolner, S. K. Sharma, M. W Lowdell, U. Qureshi, M. Robson, T. Hillyer, R. B. Pedley, W. Vervecken, R. Contreras, et al. Clearance mechanism of a mannosylated antibody-enzyme fusion protein used in experimental cancer therapy Glycobiology, January 1, 2007; 17(1): 36 - 45. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Tarcha, V. Basrur, C.-Y. Hung, M. J. Gardner, and G. T. Cole Multivalent Recombinant Protein Vaccine against Coccidioidomycosis. Infect. Immun., October 1, 2006; 74(10): 5802 - 5813. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
